Foundayo Health Insurance Denial

Legally reviewed By Scott Glovsky in Insurance and Healthcare Denials

The rise of obesity across the U.S. coincided with a 300 percent increase in prescriptions for GLP-1 drugs between 2018 and 2023. Understanding the hormones that regulate insulin production began in the 20th century. A pivotal 1984 Massachusetts study led to the groundbreaking discovery of GLP-1, revealing that it stimulated insulin secretion from the pancreas in response to food intake.

Early interest in GLP-1 primarily centered on its potential to treat diabetes rather than manage obesity. By 2010, the first GLP-1 receptor agonist, liraglutide (brand name Victoza), had received FDA approval to treat Type 2 diabetes. Studies began to reveal weight loss as an unexpected side effect of GLP-1 drugs. This prompted researchers and pharmaceutical companies to investigate the use of GLP-1 drugs for the treatment of obesity.

Semaglutide (Ozempic) became the first drug prescribed for obesity. GLP-1 enhances insulin secretion from the pancreas, reduces hunger, and increases the feeling of fullness by delaying gastric emptying.

Emerging studies suggest that GLP-1 drugs may offer benefits far beyond weight management. One of these potential benefits includes the treatment of neurodegenerative diseases like Alzheimer’s.

Weight-loss drugs like Ozempic, Wegovy, Zepbound, and newer entrants such as Foundayo have seen a meteoric rise over the past decade, transforming conversations around obesity, health, and access to care. These drugs have literally exploded into a multi-billion-dollar pharmaceutical phenomenon to the point that nearly one in eight American adults has tried a GLP-1 medication. Aggressive marketing, social media, and word-of-mouth success stories have made these drugs familiar to the majority of Americans.

If you are facing a Foundayo or any GLP-1 medication health insurance denial, don’t deal with this alone. We’re here to help. Call us at 626-243-5598 or contact us online to schedule a free consultation and get answers today.

Insurance Barriers and the Real-World Impact of GLP-1 Drug Denials

Unfortunately, access to GLP-1 drugs can be deeply unequal. For many patients, the promise of life-changing weight loss collides head-on with the bureaucratic barriers of the insurance system.

Monthly costs for GLP-1 drugs can exceed $1,000 without coverage. Even with discounts, long-term affordability remains uncertain. Only a small fraction of employer-sponsored health plans (about 20 percent) cover these medications, leaving millions of patients facing either paying the full cost or forgoing treatment.

For patients who struggle with obesity, which is linked to diabetes, heart disease, and reduced life expectancy, the denial of coverage for a drug like Foundayo can be much more than frustrating – it can adversely alter lives.

After years or decades of failed diets, exercise programs, or even surgical interventions, an individual who is told their insurer considers Foundayo or a similar drug “cosmetic,” or “not medically necessary,” can feel hopeless.

If your insurer has denied Foundayo or another GLP-1 drug, do not give up. Your next step should be to speak to an experienced health insurance denial attorney from the Law Offices of Scott Glovsky.

What is Foundayo and How Does It Work?

Originally, GLP-1 medications were only available as injections. Novo Nordisk developed the first oral GLP-1 receptor agonist, semaglutide, marketed as Rybelsus and approved by the FDA in 2019 for Type 2 diabetes. In December 2025, the FDA approved a higher-dose Wegovy pill by Novo as the first oral GLP-1 specifically for weight management. Foundayo (orforglipron) received FDA approval as a chronic weight management drug on April 1, 2026.

Foundayo was developed by Eli Lilly as a once-daily non-peptide GLP-1 receptor agonist for obese or overweight adults with at least one weight-related medical condition. The medication became available for shipment on April 6, 2026. Foundayo competes with Novo Nordisk’s Wegovy but is designed to be easier to take than earlier GLP-1 medications, as it has no strict fasting requirements.

Foundayo belongs to the same class of medications as Ozempic and Wegovy: GLP-1 receptor agonists. Your body naturally produces the GLP-1 hormone after eating, and Foundayo mimics this hormone. Foundayo helps you feel full sooner and reduces hunger signals, thus decreasing the overall food intake. Foundayo also slows the rate at which food leaves the stomach, keeping you feeling full longer and reducing the urge to snack or overeat. Like other GLP-1 drugs, Foundayo also improves insulin response, supports metabolic health, and lowers blood sugar levels. 

Foundayo is getting significant attention for several reasons. Clinical trials have shown meaningful weight loss compared with placebo, and the daily pill format is easier to integrate into your daily routine (GLP-1 drugs that require injection have been a major barrier for many patients). Foundayo has combined the powerful biology of GLP-1 drugs with a simpler, more user-friendly administration. Many people involved in the Foundayo clinical trials noted that, for the first time, their bodies felt as though they were working with them rather than against them.

What Are the Health Benefits of Foundayo?

Although weight loss is certainly the goal, the health benefits of Foundayo (orforglipron) go beyond weight loss alone. Patients taking Foundayo often experience metabolic, cardiovascular, and overall health improvements, including:

Significant and sustained weight loss from Foundayo reduces strain on joints, thus improving mobility.

Foundayo improves insulin response and lowers blood sugar levels (A1C), making the drug especially important for those with Type 2 diabetes or those at risk of developing diabetes.

Reductions in waist circumference, triglycerides, non-HDL cholesterol, and systolic blood pressure were noted in those taking Foundayo, resulting in a lower risk of heart attack and stroke and better long-term cardiovascular outcomes.

Foundayo helps patients regain control over hunger by decreasing appetite and food cravings.

Since Foundayo is designed for ongoing use, the likelihood of weight regain is greatly reduced when compared with dieting alone.

Foundayo improves lipid profiles, providing better energy balance and fat metabolism, potentially benefiting conditions like sleep apnea, hypertension, and osteoarthritis.

Early research on Foundayo and other GLP-1 drugs suggests that they could also be beneficial in reducing brain inflammation – a key driver of Alzheimer’s progression. Some researchers refer to Alzheimer’s as “Type 3 diabetes” because of how the brain processes insulin. GLP-1 medications like Foundayo may improve insulin sensitivity in the brain, support healthier neuron functions, and potentially slow cognitive decline. For all these reasons, health insurance denials of Foundayo and other GLP-1 medications can be devastating. For many patients, it is about so much more than appearance; it’s about preventing diabetes, heart disease, and long-term health decline.

Is Foundayo the Same Formula as Zepbound?

While Eli Lilly makes both Foundayo and Zepbound, they are not the same formula. Foundayo is the drug orforglipron, while Zepbound is the drug tirzepatide. Foundayo targets only GLP-1, mimicking one natural hormone that controls appetite. Zepbound targets GLP-1 and GIP, which may enhance weight loss. However, Zepbound is sold only in injection form, while Foundayo is a daily pill.

Is Foundayo or Zepbound More Effective?

Foundayo showed a 7-12 percent weight loss in clinical trials after 72 weeks. Zepbound, which targets two hormones that control appetite rather than one, showed 15-22 percent weight loss in clinical trials, depending on the dosage.

Is the Wegovy Pill or the Foundayo Pill More Effective?

Based on data from a 2026 clinical trial, the Wegovy pill appears to be slightly more effective for weight loss than Foundayo. The tradeoff is that Foundayo offers greater convenience, with no food or timing restrictions. The Wegovy pill must be taken on an empty stomach in the morning, with a minimum wait time of 30 minutes before eating or drinking anything. The Wegovy pill is a peptide, similar to the Wegovy injection, but with an absorption enhancer.

Foundayo can be taken with or without food, and, as a small molecule, it does not require the strict fasting required before taking the Wegovy pill. Those who want maximum weight loss and can maintain a strict morning routine might choose the Wegovy pill, while those who prefer more flexibility and do not want to wait 30 minutes after waking to eat or drink might prefer Foundayo. The gastrointestinal effects appeared very similar between Wegovy and Foundayo.

Who Shouldn’t Take Foundayo?

While Foundayo is well-tolerated by most people, some should not take the drug, including:

Those with a history or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, or other thyroid cancers should not take Foundayo. While not definitively proven in humans, GLP-1 drugs have caused thyroid tumors in animal studies.

Anyone who has had a serious allergic reaction to Foundayo or a similar GLP-1 medication should avoid the drug.

Those with a history of pancreatitis could be at a higher risk of recurrence when taking Foundayo or other GLP-1 medications.

Because Foundayo slows digestion, it can worsen severe chronic digestive disorders or gastroparesis, making “normal” symptoms like nausea and vomiting significantly worse.

Women who are pregnant or trying to become pregnant should not use Foundayo as the drug (and all GLP-1 drugs) are not considered safe for fetal development. Foundayo is also not recommended for those who are breastfeeding.

Those with gallbladder disease, kidney issues, Type 1 diabetes, or those on medications that affect blood sugar may be able to take Foundayo, but should use caution and undergo regular physician monitoring. 

How Much Does Foundayo Cost?

According to the manufacturer, Eli Lilly, Foundayo may cost as little as $25 per month when commercial insurance and savings programs are combined. Some insurance plans can charge up to $349 per month for Foundayo. Either of these prices will depend on your insurer’s coverage for weight-loss drugs and your eligibility for the manufacturer’s savings card. Without insurance, self-pay Foundayo through LillyDirect typically costs $149 to $299 per month, depending on dosage and whether discounts apply.

Higher dosages can cost up to $349 per month without discounts. Medicare and Medicaid typically do not cover weight-loss drugs, but some plans may approve coverage for Foundayo at about $50 per month. Discounts may limit the drug to a certain number of refills per year. While Foundayo is cheaper than many injectable weight-loss drugs, it can still be a significant financial commitment.

How Does Foundayo Compare Cost-Wise to Other GLP-1 Medications?

GLP-1 medications tend to fall into three general pricing tiers. The first tier is low-cost (which the new oral pills fall under) with a typical price of $149-$349 per month. The second tier is mid-range and generally applies to discounted injectables, with a typical price of $199-$499 per month. The third tier is high-end, or full list price, costing from $1,000 to $1,350 per month. Patients generally experience wildly varying costs for GLP-1 medications, depending on insurance coverage and access.

From least expensive to most expensive, this is how GLP-1 medications compare:

Foundayo (Wegovy pill is comparable, although it can be more expensive)

Wegovy injection

Ozempic injection

Zepbound injection

Mounjaro injection

What Are the Primary Differences Between Mounjaro/Zepbound, Saxenda, Wegovy, Ozempic, and Foundayo?

Mounjaro and Zepbound both contain the same active ingredient (tirzepatide), with the main distinction being that one is marketed for Type 2 diabetes and the other for weight loss. Both Mounjaro and Zepbound have dual ingredients (GIP + GLP-1). Ozempic and Wegovy both contain semaglutide, and, like Mounjaro and Zepbound, the distinction is between Type 2 diabetes brands and obesity brands. Ozempic and Wegovy contain GLP-1 only. Ozempic is a weekly injection, and Wegovy is either a weekly injection or a daily tablet. Saxenda contains liraglutide, a GLP-1. It is an older weight loss option and is given as a daily injection. Foundayo contains orforglipron, a GLP-1 only, and is administered as a daily pill for adult weight management.

What is the Most Effective GLP-1 Medication?

Because Zepbound and Mounjaro (tirzepatide) contain both GLP-1 and GIP mechanisms, the average weight loss is greater with these drugs than for other GLP-1-only drugs. Zepbound and Mounjaro are administered as weekly injections, targeting two metabolic pathways rather than one.

Do Most Insurance Companies Cover Foundayo?

Unfortunately, as of March 2026 more than 16 million people lack coverage for GLP-1 drugs, leaving the majority of patients to either be denied outright for coverage or to pay the high costs out of pocket. Many insurers classify weight-loss drugs as “not medically necessary,” or label them as “lifestyle” or “cosmetic” treatments. Plan-specific riders are generally required for insurers to cover Foundayo or other GLP-1 drugs.

Medicare historically has offered no coverage for GLP-1 medications, although this is slowly changing. And few states offer Medicaid GLP-1 coverage. New programs, such as Medicare’s GLP-1 “Bridge,” are set to expand access to GLP-1 medications in 2026. For those whose insurance plan does cover Foundayo, prior authorization is almost always required, and the insurer may require proof of:

BMI thresholds

Related conditions like diabetes and hypertension

Failure of other treatments

Coverage is often delayed, initially denied, or limited to specific drugs, such as Wegovy, but not Foundayo. Because Foundayo is newly approved and is specifically marketed as a weight-loss drug, rather than a drug for Type 2 diabetes, it can be harder to get insurers to cover it. Some insurance companies have not yet added Foundayo to their formularies or may restrict it more aggressively than older GLP-1 drugs. In short, coverage for Foundayo can be limited, inconsistent, and difficult to obtain. 

Can I Order Foundayo Directly from Eli Lilly?

The answer to this question is yes and no. Eli Lilly offers a direct-to-patient platform known as LillyDirect, which allows patients to fill prescriptions, access savings programs, and have the medication shipped to their home. The caveat here is that you must have a prescription for Foundayo from your physician. Foundayo – like all GLP-1 medications – is a prescription-only medication which cannot be legally purchased without a doctor’s prescription. The doctor must evaluate you, determine your eligibility, and monitor your treatment, and these requirements cannot be bypassed.

Are There Other Weight Loss Medications Currently Being Studied?

The most promising next-generation weight loss medication is CagriSema, which is a GLP-1 plus another hormone, amylin. Early data show greater weight loss than GLP-1 medications alone. Retatrutide is a triple-hormone drug currently in development that targets GLP-1, GIP, and glucagon. Early trials suggest it may be more effective for weight loss than Zepbound. New oral pill options include Amycretin, which contains GLP-1 and amylin, and Conveglipron, a new oral GLP-1 similar to Foundayo, which is currently in Phase 2-3 trials. Brenipatide is a dual GLP-1 and GIP drug, designed as a once-monthly injection that could improve both compliance and convenience.

What Should I Do If I Get a Denial for Foundayo from My Health Insurer?

If you have received a denial for Foundayo from your health insurer, you should first start with the reason for the denial. Your insurer may claim that Foundayo is not medically necessary for you, is excluded from your plan, that your prior authorization is incomplete, or that step therapy is required (i.e., you must try other drugs first). Your strategy for fighting a Foundayo denial will depend on why it was denied. Request the clinical policy bulletin for GLP-1 drugs, your plan’s formulary (drug list), and any prior authorization requirements.

This can help you determine what your insurer requires, why your request for Foundayo failed, and the best way to target your appeal for success. A strong appeal is doctor-driven, so a letter of medical necessity from your physician that contains your BMI, any related risks like diabetes or hypertension, and prior failed treatments including diet and exercise programs is essential. Supporting medical records, lab results, and documentation of health risks without treatment can all assist in a successful appeal. The goal is to show that Foundayo is medically necessary in your initial internal appeal.

If your internal appeal is unsuccessful, you can request an external, independent appeal. The external appeal is conducted by a third-party medical expert, and the decision is binding on your insurer. Depending on your specific plan, you may have legal options aside from an external appeal. And because an external appeal decision is binding, we recommend you speak with an experienced health insurance denial attorney before submitting one. If your plan technically covers GLP-1 drugs and you were denied improperly, your insurer ignored medical evidence, or you have exhausted appeals and still face denial, it could be time to speak with an attorney.

How Can the Law Offices of Scott Glovsky Help Me with My Foundayo Prescription?

A denial from Foundayo is more than a paperwork issue; it can delay access to medically necessary treatment that could improve your health and quality of life. Your insurance company may have relied on broad exclusions, outdated policies, or incomplete information to justify a denial. Fortunately, these decisions are not always final, and more to the point, are not always correct. If your claim has been denied, you have the right to challenge it.

Working with an experienced legal advocate can ensure that your case is strong, the right medical evidence is presented, and unjustified denials are appealed. Insurers count on most patients giving up following the initial rejection. Those who move forward with a strategic appeal frequently see more positive outcomes. You do not have to navigate this issue alone. Attorney Scott Glovsky is ready to advocate on your behalf, ensuring you receive justice following your Foundayo denial. Contact the Law Offices of Scott Glovsky online or call us at 626-243-5598 schedule your free consultation.